SCHEMBL25754231

SCHEMBL25754231

CC#CC(O)COCCCCCC

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.55
HTT P42858 2/20 0.53
SPHK1 Q9NYA1 1/20 0.53
LPAR5 Q9H1C0 4/20 0.46
LPAR1 Q92633 7/20 0.42
LPAR3 Q9UBY5 7/20 0.42
LPAR2 Q9HBW0 4/20 0.42
LPAR6 P43657 3/20 0.42
LPAR4 Q99677 3/20 0.42
MEN1 O00255 1/20 0.42
THRB P10828 1/20 0.42
KMT2A Q03164 1/20 0.42
MAPT P10636 1/20 0.42
PLA2G2C Q5R387 1/20 0.41
CES2 O00748 1/20 0.40
PRKD3 O94806 1/20 0.40
PRKCG P05129 1/20 0.40
PRKCB P05771 1/20 0.40
PRKCA P17252 1/20 0.40
PRKCH P24723 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25754243 0.96 USP2 (0.51) USP2HTTSPHK1LPAR5LPAR1
SCHEMBL25754247 0.96 USP2 (0.51) USP2HTTSPHK1LPAR5LPAR1
SCHEMBL25754242 0.91 USP2 (0.49) USP2HTTSPHK1LPAR5LPAR1
SCHEMBL25754224 0.87 HTT (0.48) USP2HTTSPHK1LPAR5LPAR1
SCHEMBL25754237 0.82 HTT (0.42) USP2HTTSPHK1LPAR5PLA2G2C
SCHEMBL25754235 0.82 HTT (0.42) USP2HTTSPHK1LPAR5CYP3A4
SCHEMBL25754239 0.81 HTT (0.41) USP2HTTSPHK1LPAR5CYP3A4
SCHEMBL25754240 0.81 HTT (0.41) USP2HTTSPHK1LPAR5MEN1
SCHEMBL25754230 0.80 USP2 (0.44) USP2HTTSPHK1LPAR5MEN1
SCHEMBL29169783 0.80 SPHK1 (0.69) USP2HTTSPHK1LPAR5LPAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230210999-A1 TARGETED PROTEASE DEGRADATION (TED) PLATFORM EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) 2023-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230210999-A1 TARGETED PROTEASE DEGRADATION (TED) PLATFORM UCHL3, UBE2L3, ADAM33 USP2 51/4885HTT 916/4885SPHK1 4450/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.